Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ENOSOLID
- Development stage
- Unknown
- Lead developer
- Otsuka Pharmaceutical
- Administration
- Enteral
01
Overview
ENOSOLID is a semi-solid enteral nutrition formula developed by EN Otsuka Pharmaceutical. It was approved in Japan in September 2024 for the nutritional management of patients who require enteral nutrition support, particularly those with lower maintenance energy requirements. The formula is designed to provide a balanced intake of major nutrients, vitamins, and trace elements based on 2020 Japanese nutritional standards. It specifically includes L-carnitine to support fatty acid metabolism and inulin as a dietary fiber source. It is typically administered via a gastric fistula.
- Brand names
- ENOSOLIDENOSOLID Semi Solid for Enteral Use
Beyond the preview
Go deeper on ENOSOLID.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ENOSOLID.